Are you the publisher? Claim or contact us about this channel


Embed this content in your HTML

Search

Report adult content:

click to rate:

Account: (login)

More Channels


Channel Catalog


Channel Description:

Visit One News Page for Italy news from around the world, aggregated from leading sources including newswires, newspapers and broadcast media. Search millions of archived news headlines. This feed provides the Italy news headlines.

older | 1 | .... | 1065 | 1066 | (Page 1067) | 1068 | 1069 | .... | 1077 | newer

    0 0

    Fourteen Contemporary Ocean View Villas to Debut in Early 2020

    LOS CABOS, Mexico (PRWEB) November 28, 2018

    Chileno Bay Resort & Residences, Los Cabos’ premier beachfront resort and residential villa community is expanding its current real estate offerings, breaking ground this month on its final phase of development. Fourteen contemporary ocean view units will debut in 2020, including brand new villa options with larger layouts and enhanced home design features.

    Chileno Bay Resort & Residences has seen record-breaking sales numbers totaling more than $165 million since the sales launch. Phase two, which debuted in fall 2018, has nearly sold out, fast-tracking phase three construction. With these final 14 units, owners will have the opportunity to take advantage of expansive new floorplans, including bi-level villas and one five-bedroom penthouse residence, all with an upgraded contemporary design package and state-of-the-art technology. Villas range from four- to five-bedrooms with pricing starting at $2,500,000.

    Four-bedroom units span 3,435 square feet with an additional 1,200 square feet of covered outdoor living space. The five-bedroom penthouse residence sits at 5,554 square feet and features two ocean-facing master suites, a 1,000-square-foot private rooftop pool, 2,600 square feet of covered terrace space, and a wine cellar.

    The villas are clean, light, and airy, embracing the indoor-outdoor living style of the oceanfront community with natural wood textures and flares of coastal colors. The new homes will feature an open concept with floor-to-ceiling windows and doors that open to spacious private terraces and balconies with Jacuzzis. Ground-floor villas will also offer a private pool and sun deck. All villas are equipped with indoor gourmet kitchens with Wolf and Sub-Zero appliances and well-equipped outdoor grill centers. These final 14 units will offer more shared living space and larger outdoor areas, while incorporating new cutting-edge technology. The residences will continue offering the immaculate finishes and fixtures for which the community has become known. Distinct artisanal furnishings and artwork included in the design package will exude the same contemporary feel that’s evident throughout Chileno Bay Resort & Residences.

    “We are excited to be embarking on the final phase of development after two very successful years operating as an award-winning resort and residential community,” said Mark Cooley, partner, SV Capital Partners, developers of the resort. “Our goal with these final units is to offer future buyers the most exciting new ownership opportunity in the market and continue to bring a new level of luxury to Los Cabos.”

    The Auberge-operated resort and spa at Chileno Bay has won numerous industry awards and esteemed accolades since opening in January 2017, including Travel + Leisure 2018 World’s Best Top 100, Condé Nast Traveler 2018 Best Beachfront Restaurants and Bars in Mexico, Robb Report 2017 Best of the Best, Andrew Harper’s Hideaway Report 2018 Grand Awards, and Condé Nast Traveler 2017 Readers’ Choice Awards #1 Resort in Los Cabos. Owners receive exclusive access to the resort’s luxury amenities and facilities and exceptional service of the Auberge brand.

    Chileno Bay Resorts & Residences has a 22-acre campus situated on one of Cabo’s coveted year-round swimmable beaches. The resort features a three-tiered infinity swimming pool with an oceanfront hot tub and fire pits, a spa, wellness center and movement studio, kids’ club, owners’ lounge, and h2O Cave, the waterfront sports center. Chileno Bay Resort & Residences is located within the prestigious 1,200-acre Chileno Bay master community, a Discovery Land Company development. In addition to the resort’s many luxury amenities and offerings, Chileno Bay includes a Tom Fazio-designed golf course and private beach club.

    For more information on visiting or homeownership opportunities at Chileno Bay Resort & Residences, please visit http://www.chilenobayresidences.com.

    ###

    About SV Capital Partners
    SV Capital is a boutique real estate investment and development firm with a focus on luxury resort properties. Beginning with Esperanza Resort in Cabo San Lucas, Mexico, SV’s portfolio includes eight resort projects in the U.S., Mexico, Italy and the Caribbean. SV also continues to pursue selected opportunistic real estate transactions outside the luxury resort segment with experienced operators and developers.

    About Auberge Resorts Collection
    Auberge Resorts Collection is a portfolio of extraordinary hotels, resorts, residences and private clubs. While each Auberge property possesses a unique individuality, all share a crafted approach to luxury that is expressed through captivating design, exceptional cuisine and spas, and gracious yet unobtrusive service. Properties in the Auberge Resorts Collection include: Auberge du Soleil, Calistoga Ranch and Solage, Napa Valley; Esperanza and Chileno Bay, Los Cabos, Mexico; Hotel Jerome, Aspen; Malliouhana, Anguilla; Nanuku, Fiji; Madeline Hotel and Element 52, Telluride, Colorado; Hacienda AltaGracia, Costa Rica; Mukul, Guacalito, Nicaragua; the Mayflower Inn & Spa, Washington, Conn.; White Barn Inn & Spa, Kennebunk, Maine; the Vanderbilt Hotel, Newport, R.I.; Grace Santorini and Mykonos, Greece; Auberge Beach Residences and Spa, Fort Lauderdale (opening Autumn 2018); The Lodge at Blue Sky, Park City, Utah (opening Spring 2019); Bishop’s Lodge, Santa Fe, New Mexico (opening Summer 2019); Mauna Lani, Hawaii (opening late 2019); Commodore Perry Estate, Austin; and Susurros del Corazon, Punta de Mita, Mexico (opening 2020), with several others in development. For more information about Auberge Resorts Collection, please visit http://www.aubergeresorts.com. Follow Auberge Resorts Collection on Facebook at facebook.com/AubergeResorts and on Twitter and Instagram at @AubergeResorts and #AlwaysAuberge. Reported by PRWeb 2 hours ago.

    0 0

    Dublin, Nov. 28, 2018 (GLOBE NEWSWIRE) -- The "Global Self-Adhesive Labels Market Analysis & Trends - Industry Forecast to 2027" report has been added to *ResearchAndMarkets.com's* offering.

    The Global Self-Adhesive Labels Market is poised to grow strong during the forecast period 2017 to 2027

    Some of the prominent trends that the market is witnessing include growing demand for self-adhesive labels from end-use industries and forward integrations in the value chain.

    This industry report analyzes the market estimates and forecasts of all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2015, 2016 revenue estimations are presented for 2017 and forecasts from 2018 till 2027.

    The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. With comprehensive market assessment across the major geographies such as North America, Europe, Asia Pacific, Middle East, Latin America and Rest of the world the report is a valuable asset for the existing players, new entrants and the future investors.

    The study presents detailed market analysis with inputs derived from industry professionals across the value chain. A special focus has been made on 23 countries such as U.S., Canada, Mexico, U.K., Germany, Spain, France, Italy, China, Brazil, Saudi Arabia, South Africa, etc.

    *Report Highlights:*

    · The report provides a detailed analysis on current and future market trends to identify the investment opportunities
    · Market forecasts till 2027, using estimated market values as the base numbers
    · Key market trends across the business segments, Regions and Countries
    · Key developments and strategies observed in the market
    · Market Dynamics such as Drivers, Restraints, Opportunities and other trends
    · In-depth company profiles of key players and upcoming prominent players
    · Growth prospects among the emerging nations through 2027
    · Market opportunities and recommendations for new investments

    *Key Topics Covered:*

    *1 Market Outline*
    1.1 Research Methodology
    1.2 Market Trends
    1.3 Regulatory Factors
    1.4 Technology Analysis
    1.5 Application Analysis
    1.6 Strategic Benchmarking
    1.7 Opportunity Analysis

    *2 Executive Summary *

    *3 Market Overview *
    3.1 Current Trends
    3.1.1 Growing Demand for Self-Adhesive Labels from End-User Industries
    3.1.2 Forward Integrations in the Value Chain
    3.1.3 Recent Technological Developments in Self-Adhesive Labels
    3.1.4 Growth Opportunities/Investment Opportunities
    3.2 Drivers
    3.3 Constraints
    3.4 Industry Attractiveness

    *4 Self-Adhesive Labels Market, By Type *
    4.1 Linerless
    4.2 Release Liner

    *5 Self-Adhesive Labels Market, By Nature*
    5.1 Permanent
    5.2 Removable
    5.3 Repositionable

    *6 Self-Adhesive Labels Market, By Composition*
    6.1 Production Process
    6.2 Composition of Self-Adhesive Labels
    6.2.1 Adhesive
    6.2.2 Facestock or Face Material
    6.2.3 Release Liner Or Backing

    *7 Self-Adhesive Labels Market, By Technology*
    7.1 Digital Printing
    7.2 Flexography
    7.3 Gravure
    7.4 Letterpress
    7.5 Lithography
    7.6 Offset
    7.7 Screen Printing

    *8 Self-Adhesive Labels Market, By Application*
    8.1 Food & Beverages
    8.2 Consumer Durables
    8.3 Home & Personal Care Products
    8.4 Pharmaceuticals
    8.5 Retailers and Supermarkets
    8.6 Tracking, Logistics & Transport
    8.7 Other Applications

    *9 Self-Adhesive Labels Market, By Material Type*
    9.1 Paper
    9.2 Plastics
    9.2.1 Poly Ethylene Terephthalate (PET)
    9.2.2 Polyethylene (PE)
    9.2.3 Polypropylene (PP)

    *10 Self-Adhesive Labels Market, By Adhesive Type*
    10.1 Acrylic Adhesives
    10.2 Hot Melt Adhesives
    10.3 Removable Adhesives
    10.4 Other Adhesive Types

    *11 Self-Adhesive Labels Market, By Geography*
    11.1 North America
    11.1.1 US
    11.1.2 Canada
    11.1.3 Mexico
    11.2 Europe
    11.2.1 France
    11.2.2 Germany
    11.2.3 Italy
    11.2.4 Spain
    11.2.5 UK
    11.2.6 Rest of Europe
    11.3 Asia Pacific
    11.3.1 China
    11.3.2 Japan
    11.3.3 India
    11.3.4 Australia
    11.3.5 New Zealand
    11.3.6 Rest of Asia Pacific
    11.4 Middle East
    11.4.1 Saudi Arabia
    11.4.2 UAE
    11.4.3 Rest of Middle East
    11.5 Latin America
    11.5.1 Argentina
    11.5.2 Brazil
    11.5.3 Rest of Latin America
    11.6 Rest of the World (RoW)
    11.6.1 South Africa
    11.6.2 Others

    *12 Key Player Activities *
    12.1 Mergers & Acquisitions
    12.2 Partnerships, Joint Venture's, Collaborations and Agreements
    12.3 Product Launch & Expansions
    12.4 Other Activities

    *13 Leading Companies*· Americk Packaging Group
    · Avery Dennison
    · Aztec Label
    · BSP Labels
    · C S Labels
    · CCL Industries
    · Coveris Holdings S.A.
    · Etiquette Labels
    · Etis Slovakia A.S.
    · Fuji Seal International
    · Hansol Paper
    · Huhtamaki
    · Inland Label and Marketing Services
    · Label Craft
    · Lintec
    · Multi-Color Corporation
    · Muroll
    · Reflex Labels
    · Royston Labels
    · Secura Labels
    · SVS Spol S R.O.
    · Terragene
    · Torraspapel Adestor (Part of Lecta Group)
    · UPM-Kymmene

    For more information about this report visit https://www.researchandmarkets.com/research/729rlc/global?w=12
    Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

    CONTACT:
    CONTACT: ResearchAndMarkets.com
    Laura Wood, Senior Press Manager
    press@researchandmarkets.com
    For E.S.T Office Hours Call 1-917-300-0470
    For U.S./CAN Toll Free Call 1-800-526-8630
    For GMT Office Hours Call +353-1-416-8900
    Related Topics: Stationery and Greeting Cards, Labels Reported by GlobeNewswire 1 hour ago.

    0 0

    Automating Train Operations to Fuel Demand for Train Control and Management Systems Market

    Albany, New York, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Few leading players including Bombardier Inc., Siemens AG, Alstom S.A., and Toshiba Corp. have made the global train control and management systems market highly competitive. In 2015, these players held 45% share in the global market. In the coming years, the market is likely to witness intense competition among the players, as large numbers of new players are entering in the global market. Leading players in the market are focusing on different strategies to expand their geographical reach and to gain larger share in the market.

    According to Transparency Market Research, the global train control and management systems market is steady 8.2% CAGR between 2016 and 2024. Rising at this rate, the market is expected to reach a valuation of US$5.01 bn by the end of 2024.  In 2015, the market valuation was US$2.5 bn.

    *Request to View Sample of Report at *https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=17663

    On the basis of train type, the metros and high speed trains segment held maximum share in 2015. The dominance of this segment is based on increasing investments from governments to modernize rail infrastructure and to assist in transit projects. On regional front, Europe is leading the global train control and management systems market due to the presence of leading manufacturers of this market. Over the course of eight years, this region is expected to rise at a growth rate of 7.70%. Asia Pacific is likely to offer lucrative growth opportunities for this market.

    *Expanding Global Population to Fuel Demand for Train Control and Management Systems*

    Growing global population is considered as the key factor driving the demand in the train control and management systems market.  The rapid growth of rail transit systems across the globe and need for technologically advanced transportation infrastructure have fueled the demand for train control and management systems. In addition, larger use of public transportation helps in reducing traffic congestion, greenhouse gas emission, and unstable fuel prices. This is also likely to augment the train control and management systems. Furthermore, train control systems increase reliability and efficiency of trains and help in reducing their response time due to automating the operations of the train.

    *Request PDF Brochure of Report at *https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=17663

    *Lack of Interoperability to Hamper Market Growth *

    High maintenance and infrastructural costs are the key restraining factors deterring the growth of this market. In addition to that, lack of interoperability as various national rail networks have set various technical specifications for the rail infrastructure is also expected to impede the market’s growth.  System failure or system malfunction that can lead to derailment and collisions of trains are some of the other factor obstructing the market’s growth. These limitations could be curtailed through high investments in the intercity high-speed rail lines. Moreover, centralized control over a large number of subsystems of trains by deploying train control and management systems is also expected to reduce the above-mentioned restraints.

    *Request for Custom Research at *https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=17663

    The information presented in this review is based on a TMR report, titled “Train Control and Management Systems Market (Train Type - Metros and High Speed Trains, Electric Multiple Units, and Diesel Multiple Units; Component Type - Computer Control Units, Modular Input/output Devices, Mobile Communication Gateway, and Human Machine Interfaces; Train Control Solution Type - Positive Train Control, Integrated Train Control, and Communication Based Train Control) - Global Industry Analysis, Trend, Size, Share and Forecast 2016 - 2024.”

    *Download Report TOC for in-depth analysis at* https://www.transparencymarketresearch.com/report-toc/17663

    *The Global Train Control and Management Systems Market has been segmented as presented below:*

    *Global Train Control and Management Systems Market: By Train Type*

    · Metros and High Speed Trains
    · Electric Multiple Units
    · Diesel Multiple Units 

    *Global Train Control and Management Systems Market: By Component Type*

    · Computer Control Units
    · Modular Input/output Devices
    · Mobile Communication Gateway
    · Human Machine Interfaces 

    *Global Train Control and Management Systems Market: By Train Control Solution Type*

    · Positive Train Control
    · Integrated Train Control
    · Communication Based Train Control 

    *Global Train Control and Management Systems Market: Geography*

    · *North America*

    · U.S.
    · Canada

    · *Europe*

    · U.K.
    · Italy
    · Spain
    · France
    · Germany
    · Rest Of Europe

    · *Asia Pacific Excluding Japan*

    · China
    · India
    · ASEAN
    · Rest Of Asia Pacific
    · Japan

    · *Latin America*

    · Brazil
    · Mexico
    · Rest of South America

    · *Middle East & Africa (MEA)*

    · GCC
    · South Africa
    · Rest of MEA

    *Browse More **Automotive & Transport Market Research Reports*

    *Popular Report by TMR:*

    · *Autonomous Trains Technology Market - *Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025: https://www.transparencymarketresearch.com/autonomous-trains-technology-market.html
    · *Ride sharing Market - *Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 – 2026: * *

    https://www.transparencymarketresearch.com/ride-sharing-market.html

    · *Electric Vehicle Charging Station Market - *Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026: https://www.transparencymarketresearch.com/electric-vehicle-charging-station-market-2018-2026.html

    *About Us*

    Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

    Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

    TMR believes that unison of solutions for *clients-specific problems with *right methodology of research is the key to help enterprises reach right decision.”

    *Contact*

    Mr. Rohit Bhisey
    Transparency Market Research
    State Tower
    90 State Street,
    Suite 700,
    Albany, NY - 12207
    United States
    Tel: +1-518-618-1030
    USA - Canada Toll Free: 866-552-3453
    *Email: *sales@transparencymarketresearch.com
    *Website: *https://www.transparencymarketresearch.com

    Research Blog: https://transparencyjournal.com Reported by GlobeNewswire 1 hour ago.

    0 0

    Datalogic is pleased to announce SLS-SA5, the stand alone model of the LASER SENTINEL safety laser scanners family.

    BOLOGNA, Italy (PRWEB) November 28, 2018

    Datalogic, a global leader in the automatic data capture and process automation markets, is pleased to announce SLS-SA5, the stand alone model of the LASER SENTINEL safety laser scanners family. The first version of the Datalogic innovative solution for safe area scanning, SLS-B5, was released last year, well acclaimed by the manufacturing industry, that appreciated the easy programming of the system with intuitive graphic user interface and the high detection capability.

    Today, Datalogic proudly reveals a new model with even more features that will cover a larger variety of applications in factory automation and intralogistics. The world's largest automotive companies have already shown great interest in Datalogic's new Safety Laser Scanner.

    SLS-SA5 is a complete application-oriented solution based on the safe monitoring of a two-dimensional area including all functions needed for static horizontal and vertical applications (such as robot cells, machine perimeter protection, machine opening protections, etc.) as well as dynamic applications (automated guided vehicles, automated guided carts and forklifts) in a compact device with high level detection performances. Innovative optical features and signal filtering make the Laser Sentinel extremely reliable in industrial environments where dust, dirt or light interferences can’t be avoided.

    “Safety in the manufacturing industry has certainly improved over the last decades, nonetheless the concerns are still numerous and very real. People remain at the center of many processes, despite the increasing automation, and are still very much exposed to serious injuries. By prioritizing safety, a manufacturing company can set the values for the entire workforce. The safety laser scanner is used to detect people who are approaching a hazardous area, before reaching it, in order to prevent hazardous circumstances (for example, a mechanical movement) that may cause injuries or an accident. The protective detection is done by defining a safety area, whose shape and dimensions must be designed according to the risk assessment of the machine. The user must consider the position of the hazardous point, the shape of the machine and the surrounding environment as well as the time needed to stop any dangerous approach,” said Paolo Zanetta, Datalogic Product Marketing Manager. “Among the new features are the possibility to switch dynamically between up to 6 different safety zones, to program reference points for a safe use in vertical applications, and the integration of muting function,” added Zanetta.

    Like any other safety product designed and produced by Datalogic, LASER SENTINEL has been certified according to the most recent European safety standard harmonized with the Machine Directive, with the supervision and control of the independent and renowned TÜV SÜD. LASER SENTINEL is also cULus Listed for the Canada and US markets.

    Datalogic is a global leader in the automatic data capture and process automation markets, specialized in the designing and production of bar code readers, mobile computers, sensors for detection, measurement and safety, RFID vision and laser marking systems. Datalogic solutions help to increase the efficiency and quality of processes in the Retail, Manufacturing, Transportation & Logistics and Healthcare industries, along the entire value chain.

    The world's leading players in the four reference industries use Datalogic products, certain of the attention to the customer and of the quality of the products that the Group has been offering for 45 years.

    Today Datalogic Group, headquartered in Bologna (Italy), employs approximately 3,100 staff worldwide, distributed in 30 countries, with manufacturing and repair facilities in the USA, Brazil, Italy, Slovakia, Hungary and Vietnam. In 2017 Datalogic had a turnover of 606 million Euro and invested over 55 million Euros in Research & Development, with an asset of more than 1,200 patents in multiple jurisdictions.

    Datalogic S.p.A. is listed in the STAR segment of the Italian Stock Exchange since 2001 as DAL.MI. More information about Datalogic at http://www.datalogic.com.

    Datalogic and the Datalogic logo are registered trademarks of Datalogic S.p.A. in many countries, including the U.S.A. and the E.U. Reported by PRWeb 40 minutes ago.

    0 0

    One Liverpool midfielder has opened the door on a shock return to Serie A in the future after reflecting on his time in Italy.

    The post Liverpool star names one career regret as he opens door to shock Serie A return appeared first on teamtalk.com. Reported by Team Talk 25 minutes ago.

    0 0

    The Italian government passed a law that clamps down on asylum rights and boosts funds for police, handing Interior Minister and right-wing League party leader Matteo Salvini his first major legislative win. Reported by Reuters 3 hours ago.

    0 0

    Rare disease therapy honored with seven Prix Galien awards, including six independent country recognitions, for innovation in treating spinal muscular atrophy

    CAMBRIDGE, Mass., Nov. 29, 2018 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has been awarded the 2018 International Prix Galien as Best Biotechnology Product for SPINRAZA (nusinersen), the first and only treatment for spinal muscular atrophy (SMA). The prestigious honor marks the seventh Prix Galien for SPINRAZA, following country recognitions in the U.S., Germany, Italy, Belgium-Luxembourg, the Netherlands and the U.K. The international award was presented at a ceremony in Dakar, Senegal on November 28, 2018.“We are honored that the Galien Foundation continues to recognize the groundbreaking science and profound clinical impact of SPINRAZA with this international award,” said Michel Vounatsos, chief executive officer of Biogen. “The ability to bring the first and only therapy to people living with SMA is the result of a close collaboration with the SMA community, academia, researchers and our colleagues at Ionis, which has made a meaningful difference in this area of high unmet medical need.”

    The International Prix Galien is given every two years by Prix Galien International Committee members in recognition of excellence in scientific innovation to improve human health. To qualify for International Prix Galien consideration, nominees must have won a Prix Galien in an individual member country.

    SMA is a progressive, debilitating neuromuscular disease that impacts infants, children and adults. It affects approximately one in every 10,000 live births and results in muscle weakness which can take away a person’s ability to walk, eat and ultimately breathe.^1 The U.S. Food and Drug Administration (FDA) approved SPINRAZA on December 23, 2016, under priority review for the treatment of SMA in pediatric and adult patients. In June 2017 SPINRAZA was granted marketing authorization in the European Union to treat individuals with 5q SMA, the most common form of the disease representing approximately 95 percent of all SMA cases.^2

    *About The Galien Foundation*
    The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. The Foundation oversees and directs activities in the USA for the Prix Galien, an international award that recognizes outstanding achievements in improving the human condition through the development of innovative therapies. The Prix Galien was created in France in 1970 in honor of Galen, the father of medical science and modern pharmacology.

    *SPINRAZA Program Status *
    SPINRAZA is the first and only approved medicine for the treatment of spinal muscular atrophy (SMA) and is currently approved in the U.S., the European Union, and Japan, among other countries. Biogen has submitted regulatory filings in additional countries and plans to initiate additional filings in other countries. As of September 30, 2018 nearly 6,000 individuals with SMA are being treated with SPINRAZA worldwide, based on patients across the post-marketing setting, Expanded Access Program (EAP) and clinical trial participants.

    To support the urgent need for treatment for the most severely affected individuals living with SMA, Biogen initiated one of the largest, global, pre-approval EAPs in any rare disease, providing access to therapy free of charge. From its launch to June 30, 2018, the EAP has provided treatment access to more than 750 patients across 29 countries. Biogen also supports a Named Patient Sales Program (NPP), which allows access to SPINRAZA in countries where it is not commercially available.

    Biogen licensed the global rights to develop, manufacture and commercialize SPINRAZA from Ionis Pharmaceuticals (Nasdaq: IONS), a leader in antisense therapeutics. Biogen and Ionis conducted an innovative clinical development program, the largest of its kind in SMA, that moved SPINRAZA from its first dose in humans in 2011 to its first regulatory approval in five years.

    *About SMA^1,3-6*
    SMA is a rare, genetic, neuromuscular disease that is characterized by loss of motor neurons in the spinal cord and lower brain stem, resulting in severe and progressive muscle atrophy and weakness. Ultimately, individuals with SMA may lose the ability to walk and can have difficulty performing the basic functions of life, such as breathing and swallowing, which results in significant healthcare intervention and caregiver assistance. Left untreated, the majority of infants with the most severe form of the disease do not live to see their second birthday without respiratory intervention.

    Due to a deletion of, or mutation in, the SMN1 gene, people with SMA do not produce enough survival motor neuron (SMN) protein, which is critical for the maintenance of motor neurons. The severity of SMA correlates with the amount of SMN protein an individual has. People with Type 1 SMA, the form that requires the most intensive and supportive care, produce very little SMN protein and do not achieve the ability to sit without support or live beyond two years without respiratory support. People with Type 2 and Type 3 SMA produce greater amounts of SMN protein and have less severe, but still life-altering forms of SMA.

    *About SPINRAZA^® (nusinersen)**^7-10*
    SPINRAZA is an antisense oligonucleotide (ASO), developed using Ionis’ proprietary antisense technology, that is designed to treat SMA caused by mutations or deletions in the SMN1 gene, located in chromosome 5q, that leads to a deficiency in SMN protein. SPINRAZA alters the splicing of SMN2 pre-mRNA in order to increase production of full-length SMN protein. ASOs are short synthetic strings of nucleotides designed to selectively bind to target RNA and regulate gene expression. Through use of this technology, SPINRAZA has been shown to increase the amount of full-length SMN protein in individuals with SMA.

    SPINRAZA must be administered via intrathecal injection, which delivers therapies directly into the cerebrospinal fluid (CSF) around the spinal cord, where motor neurons degenerate in individuals with SMA due to insufficient levels of SMN protein.

    In the clinical trial program, SPINRAZA demonstrated a favorable benefit-risk profile. The most common adverse reactions that occurred in the SPINRAZA group were respiratory infection and constipation. Serious adverse reactions of atelectasis were more frequent in SPINRAZA-treated patients. Coagulation abnormalities and thrombocytopenia, including acute severe thrombocytopenia, have been observed after administration of some ASOs. Individuals may be at increased risk of bleeding complications. Renal toxicity has been observed after administration of some ASOs. SPINRAZA is present in and excreted by the kidney.

    Please click for Important Safety Information and full Prescribing Information in the U.S. and Europe, or visit your respective country’s product website. 

    *About Biogen*
    At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy and is focused on advancing neuroscience research programs in Alzheimer’s disease and dementia, multiple sclerosis and neuroimmunology, movement disorders, neuromuscular disorders, pain, ophthalmology, neuropsychiatry and acute neurology. Biogen also manufactures and commercializes biosimilars of advanced biologics.

    We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media – Twitter, LinkedIn, Facebook, YouTube.

    *Biogen Safe Harbor *
    This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, relating to the potential benefits, safety and efficacy of SPINRAZA; the results of certain real-world data; the status of our current regulatory filings; our plans for additional regulatory filings in other jurisdictions; planning and timing for commercial launch; and availability of patient access and reimbursement pathways, which may vary on a country-by-country basis. These forward-looking statements may be accompanied by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,” “potential,” “will” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or the scientific data presented.

    These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation uncertainty of success in the commercialization of SPINRAZA, which may be impacted by, among other things, the level of preparedness of healthcare providers to treat patients, difficulties in obtaining or changes in the availability of reimbursement for SPINRAZA, the effectiveness of sales and marketing efforts, problems with the manufacturing process for SPINRAZA, the occurrence of adverse safety events and/or unexpected concerns that may arise from additional data or analysis; regulatory authorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of SPINRAZA or expansion of product labeling; the occurrence of adverse safety events; risks of unexpected costs or delays; we may encounter other unexpected hurdles; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; product liability claims; and third party collaboration risks. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in our most recent annual or quarterly report and in other reports we have filed with the U.S. Securities and Exchange Commission. These statements are based on our current beliefs and expectations and speak only as of the date of this press release. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

    1. Darras B, Markowitz J, Monani U, De Vivo D. Chapter 8 - Spinal Muscular Atrophies. In: Vivo BTD, ed. Neuromuscular Disorders of Infancy, Childhood, and Adolescence (Second Edition). San Diego: Academic Press; 2015:117-145.

    2. Farrar. Genetics of spinal muscular atrophy: progress and challenges. Neurotherapeutics. 2015 Apr;12(2):290-302

    3. Lefebvre S, Burglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell.1995;80(1):155-165.

    4. Mailman MD, Heinz JW, Papp AC, et al. Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med. 2002;4(1):20-26.

    5. Monani UR, Lorson CL, Parsons DW, et al. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet. 1999;8(7):1177-1183.

    6. Peeters K, Chamova T, Jordanova A. Clinical and genetic diversity of SMN1-negative proximal spinal muscular atrophies. Brain.2014;137(Pt 11):2879-2896.

    7. Hua Y, Sahashi K, Hung G, Rigo F, Passini MA, Bennett CF, Krainer AR. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev. 2010 Aug 1; 24(15):16344-44.

    8. Finkel R, Chiriboga C, Vajsar J, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016;388(10063):3017-3026.

    9. Evers MM, Toonen LJ, van Roon-Mom WM. Antisense oligonucleotides in therapy for neurodegenerative disorders. Adv Drug Deliv Rev. 2015;87:90-103.

    10. Lunn MR, Wang CH. Spinal muscular atrophy. Lancet. 2008;371(9630):2120-2133.

         
    MEDIA CONTACT:   INVESTOR CONTACT:
         
    David Caouette   Matt Calistri
    +1 617 679 4945   +1 781 464 2442
    public.affairs@biogen.com   IR@biogen.com
          Reported by GlobeNewswire 4 hours ago.

    0 0

    Fiat Chrysler pledged on Thursday to spend more than 5 billion euros ($5.7 billion) on new models and engines in Italy between 2019-2021 in a bid to fill under-utilized plants, conserve jobs and boost operating margins in Europe. Reported by Reuters 3 hours ago.

    0 0

    Dublin, Nov. 29, 2018 (GLOBE NEWSWIRE) -- The "Global Smart Pills Market Analysis & Trends - Industry Forecast to 2027" report has been added to *ResearchAndMarkets.com's* offering.

    Some of the prominent trends that the market is witnessing include rise in incidences of colon cancer and rapid growth in drug development process.

    This industry report analyzes the market estimates and forecasts of all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2015, 2016 revenue estimations are presented for 2017 and forecasts from 2018 till 2027.

    The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. With comprehensive market assessment across the major geographies such as North America, Europe, Asia Pacific, Middle East, Latin America and Rest of the world the report is a valuable asset for the existing players, new entrants and the future investors.

    *Scope of the Report*· Based on Disease Indications, the market is categorized into crohn's disease, small bowel tumors, inherited polyposis syndromes, occult gi bleeding and celiac disease.
    · Depending on Target Area, the market is segregated into small intestine, esophagus, large intestine and stomach.
    · Based on Technology, the market is categorized into gastrointestinal monitoring technology, drug delivery technology and capsule endoscopy technology.
    · In addition, gastrointestinal monitoring technology segment if further classified into multi-parameter monitoring and single-parameter monitoring. Capsule endoscopy technology segment is divided into workstations, capsule endoscope and recorders.
    · Depending on End User, the market is segmented into diagnostic center, hospital and research institute.
    · By Application, the market is divided into patient monitoring, drug delivery, mirocam, upgraded mirocam, advanced capsule endoscope, tools, capsule endoscopy, small-bowel video capsule endoscopy, colon capsule endoscopy, omom capsule endoscopy and other applications.
    · In addition, Capsule Endoscopy segment is further segmented into abdominal pain, ulcers, iron deficiency, unexplained bleeding and polyps & tumors.
    · OMOM Capsule Endoscopy is classified into storable capsule endoscope, ph capsule wireless monitoring system, small bowel capsule endoscopy, controllable capsule endoscopy and impedance-ph monitoring system.

    The study presents detailed market analysis with inputs derived from industry professionals across the value chain. A special focus has been made on 23 countries such as U.S., Canada, Mexico, U.K., Germany, Spain, France, Italy, China, Brazil, Saudi Arabia, South Africa, etc. The market data is gathered from extensive primary interviews and secondary research. The market size is calculated based on the revenue generated through sales from all the given segments and sub segments in the research scope. The market sizing analysis includes both top-down and bottom-up approaches for data validation and accuracy measures.

    *Report Highlights:*

    · The report provides a detailed analysis on current and future market trends to identify the investment opportunities
    · Market forecasts till 2027, using estimated market values as the base numbers
    · Key market trends across the business segments, Regions and Countries
    · Key developments and strategies observed in the market
    · Market Dynamics such as Drivers, Restraints, Opportunities and other trends
    · In-depth company profiles of key players and upcoming prominent players
    · Growth prospects among the emerging nations through 2027
    · Market opportunities and recommendations for new investments

    *Key Topics Covered:*

    1 Market Outline

    2 Executive Summary

    3 Market Overview
    3.1 Current Trends
    3.1.1 Rise in Incidences of Colon Cancer
    3.1.2 Rapid Growth in Drug Development Process
    3.1.3 Recent Technological Developments in Smart Pills
    3.1.4 Growth Opportunities/Investment Opportunities
    3.2 Drivers
    3.3 Constraints
    3.4 Industry Attractiveness

    4 Smart Pills Market, By Disease Indications
    4.1 Crohn's Disease
    4.2 Small Bowel Tumors
    4.3 Inherited Polyposis Syndromes
    4.4 Occult GI Bleeding
    4.5 Celiac Disease

    5 Smart Pills Market, By Target Area
    5.1 Small Intestine
    5.2 Esophagus
    5.3 Large Intestine
    5.4 Stomach

    6 Smart Pills Market, By Technology
    6.1 Gastrointestinal Monitoring Technology
    6.1.1 Multi-Parameter Monitoring
    6.1.2 Single-Parameter Monitoring
    6.2 Drug Delivery Technology
    6.3 Capsule Endoscopy Technology
    6.3.1 Workstations
    6.3.2 Capsule Endoscope
    6.3.3 Recorders

    7 Smart Pills Market, By End User
    7.1 Diagnostic Center
    7.2 Hospital
    7.3 Research Institute

    8 Smart Pills Market, By Application
    8.1 Patient Monitoring
    8.2 Drug Delivery
    8.3 MiroCam
    8.4 Upgraded MiroCam
    8.5 Advanced Capsule Endoscope
    8.6 Tools
    8.7 Capsule Endoscopy
    8.7.1 Abdominal Pain
    8.7.2 Ulcers
    8.7.3 Iron Deficiency
    8.7.4 Unexplained Bleeding
    8.7.5 Polyps & Tumors
    8.8 Small-bowl Video Capsule Endoscopy
    8.9 Colon Capsule Endoscopy
    8.10 OMOM Capsule Endoscopy
    8.10.1 Storable Capsule Endoscope
    8.10.2 pH Capsule Wireless Monitoring System
    8.10.3 Small Bowel Capsule Endoscopy
    8.10.4 Controllable Capsule Endoscopy
    8.10.5 Impedance-pH Monitoring System
    8.11 Other Applications

    9 Smart Pills Market, By Geography

    10 Key Player Activities
    10.1 Mergers & Acquisitions
    10.2 Partnerships, Joint Venture's, Collaborations and Agreements
    10.3 Product Launch & Expansions
    10.4 Other Activities

    11 Leading Companies· Fujifilm Holdings Corporation
    · Medimetrics S.A. DE C.V
    · BDD Ltd.
    · Acamp
    · Cerner Corporation
    · Olympus Corporation
    · Pentax Medical Company
    · Proteus Digital Health, Inc.
    · Boston Scientific Corporation
    · Capsovision, Inc.
    · Ge Healthcare
    · Given Imaging, Inc
    · Karl Storz Gmbh & Co. KG
    · Medisafe

    For more information about this report visit https://www.researchandmarkets.com/research/m394pw/global_smart?w=12
    Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

    CONTACT:
    CONTACT: ResearchAndMarkets.com
    Laura Wood, Senior Press Manager
    press@researchandmarkets.com
    For E.S.T Office Hours Call 1-917-300-0470
    For U.S./CAN Toll Free Call 1-800-526-8630
    For GMT Office Hours Call +353-1-416-8900
    Related Topics: Medical Devices, Drug Delivery Reported by GlobeNewswire 3 hours ago.

    0 0
  • 11/29/18--04:54: Juventus want Fernandes
  • According to reports in Italy, Juventus are very interested in the possibility of bringing Gedson Fernandes to the club. The 19 year old sensation first made a splash in the first team earlier this year, and ever since debuting he has been turning heads left, right and centre. While the Portuguese league isn’t quite as […]

    The post Juventus want Fernandes appeared first on Soccer News. Reported by SoccerNews.com 3 hours ago.

    0 0

    Highly-Programmable Pluribus Adaptive Cloud Fabric Ensures Simplicity, Agility, and Resiliency

    San Jose, Nov. 29, 2018 (GLOBE NEWSWIRE) -- SAN JOSE, CALIF. – November 29, 2018 – Pluribus Networks today announced that Econocom Italia, one of Europe’s leading enablers of digital transformation, has selected the Pluribus Networks solution, which includes the Netvisor ONE network operating system (NOS), Adaptive Cloud Fabric™ and Pluribus UNUM Management Platform, to deliver Naboo Cloud, a new elastic hybrid cloud platform. The deal was enabled by Pluribus Networks’ partner Dell EMC. Pluribus currently supports a wide range of Dell EMC Open Networking switches, allowing Econocom Italia to benefit from the disruptive economics of open networking.

    *Econocom Italia’s Naboo Cloud *

    Econocom Italia designs and accelerates enterprise customers’ digital transformation and delivers a variety of digital, consulting and managed services to enable the successful implementation of large-scale digital projects.

    Italy’s first software defined offering that integrates connectivity and co-location, Naboo Cloud is a high-performance hybrid cloud platform built across multiple geographically dispersed data centers in Italy, delivering a “gateway of services” to large and mid-sized businesses. Naboo Cloud includes cloud applications, co-location and hosting, managed services, virtual desktop infrastructure, high performance database virtualization, mobile device management, and consulting services. Naboo Cloud offers complete integration between public and private cloud environments through a single management platform for monitoring, provisioning and orchestrating the development and distribution of containerized applications in OpenStack environments.

    "The programmability, performance and economics of our software-defined infrastructure is critical to our success and the foundation of our customer experience. Pluribus’ distributed, controllerless Adaptive Cloud Fabric architecture automates plug and play operation with Econocom Italia’s existing network infrastructure. Pluribus is delivering a non-disruptive and transparent solution that makes it easier for Econocom Italia to deliver, manage, and secure service delivery,” said Paolo Bombonati, Econocom Italia's chief operating officer.

    *Pluribus Solution for Econocom Italia*

    The Pluribus Linux-based Netvisor ONE network operating system (NOS) featuring the Adaptive Cloud Fabric (ACF) running on Dell EMC Open Networking Switches was selected because of the solution’s ability to not only bring open networking economics to Naboo Cloud, but for its ability to span and unify multiple geographically dispersed data centers. The ACF leverages next-generation software-defined networking (SDN) to create a network fabric that federates together a large number of switches to appear as one logical switch. Unlike competitive offerings, the ACF does so without the need for an external SDN controller. This controllerless next-generation SDN approach facilitates seamless insertion into existing brownfield network environments and dramatically reduces operating costs and the potential for human error while increasing resiliency with no single point of failure.

    Econocom Italia also deployed Pluribus Unum which manages the network at the NOS and fabric level with a rich graphical user interface along with Pluribus Insight Analytics, providing deep network analysis down to the network flow level. The Pluribus ACF solution is integrated with VMware, which allows the provisioning of virtual machines and associated network connections directly from vCenter. The solution also interfaces with OpenStack enabling the migration of customers on Naboo Cloud from VMware to OpenStack if they prefer that option.

    “Econocom Italia is helping businesses achieve their digital transformation goals in a highly efficient and integrated manner. In choosing Pluribus, and leveraging Dell EMC Open Networking solutions, Econocom Italia can deliver a cost-effective service that provides customers with greater agility and operational control, accelerating their journey to the multi-cloud world,” said Kumar Srikantan, Pluribus Networks’ president and chief executive officer.

    *About Econocom*

    Econocom finances and accelerates companies’ digital transformation. With more than 10,700 employees in 19 countries and revenue of €3 billion, Econocom has all the requisite abilities to ensure the successful implementation of large-scale digital projects: consulting, sourcing and technology management & financing of digital assets, infrastructure, application and business solution services, and project financing. Econocom has adopted European company status (Societas Europaea). The Econocom Group share has been listed on Euronext Brussels since 1986. It is part of the BEL Mid and Family Business indices.

    *About Pluribus Networks*

    The Pluribus Networks approach to next-generation data center architectures delivers an open, virtualized and highly programmable network fabric that ensures simplicity, agility, and resiliency with simplified management and white-box economics. Enabling freedom from legacy network constraints, the Pluribus Adaptive Cloud Fabric™ is powered by the Netvisor ONE OS and a wide range of Open Networking switches including devices from Dell EMC, D-Link Systems, Edge-core, and the Pluribus Freedom™ series network switches. These next-generation data center switches are purpose-built for software-defined and virtualized data centers of all sizes and deliver a cost-effective, high-performance, and scalable network foundation for infrastructure and application modernization. The combination of Open Networking hardware and the Pluribus Adaptive Cloud Fabric delivers a capability set that empowers any size organization to do more with their next-generation data center architectures while eliminating complexities, reducing risk, and speeding the time to value.

    # # #

    CONTACT: Charlie Guyer
    Guyer Group
    charlie@guyergroup.com Reported by GlobeNewswire 3 hours ago.

    0 0

    Bale to follow Ronaldo to Serie A? 'Nothing is impossible', says Real Madrid star's agent The Wales international continues to generate transfer talk and it could be that he treads a similar path to a former colleague and heads to Italy Reported by Goal.com 3 hours ago.

    0 0

    MILAN (AP) — Fiat Chrysler Automobiles CEO Mike Manley says the Italian-American carmaker will build a fully electric version of the 500 city car and a compact Alfa Romeo SUV at plants in Italy.Manley and other executives met with... Reported by New Zealand Herald 3 hours ago.

    0 0

    Dublin, Nov. 29, 2018 (GLOBE NEWSWIRE) -- The "Global Personalized Medicine Market Analysis & Trends - Industry Forecast to 2027" report has been added to *ResearchAndMarkets.com's* offering.

    Some of the prominent trends that the market is witnessing include rising prevalence of chronic diseases, usage of combination biomarkers for diagnostics and adoption of complementary medicine.

    This industry report analyzes the market estimates and forecasts of all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2015, 2016 revenue estimations are presented for 2017 and forecasts from 2018 till 2027.

    The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. With comprehensive market assessment across the major geographies such as North America, Europe, Asia Pacific, Middle East, Latin America and Rest of the world the report is a valuable asset for the existing players, new entrants and the future investors.

    The study presents detailed market analysis with inputs derived from industry professionals across the value chain. A special focus has been made on 23 countries such as U.S., Canada, Mexico, U.K., Germany, Spain, France, Italy, China, Brazil, Saudi Arabia, South Africa, etc.*Scope of the Report*· On the basis of Therapeutic area, the market is divided into Oncology, Neurology, Cardiology, Antiviral and Psychiatry.
    · Based on the Product, the market is divided into Personalized Medicine Therapeutics, Personalized Medicine Diagnostics, Personalized Medical Care, and Personalized Nutrition & Wellness.
    · Personalized Medicine Therapeutics segment is further divided into Pharmaceuticals, Genomic Medicine, and Medical Devices.
    · Personalized Medicine Diagnostics segment is again bifurcated into Genetic Testing, Direct-to-consumer Diagnostics, Esoteric Lab Services and Lab Tests.
    · Personalized Medical Care is divided into Telemedicine, Healthcare Information Technology, and Diseases Management.
    · Personalized Nutrition & Wellness is segmented into Retail Nutrition, Complementary Medicine and Alternative Medicine.
    · By application the market is divided into Companion Diagnostics, Biomarker identification, Health Informatics, Clinical Research, Cancer Management, Infectious Diseases, Central Nervous System (Cns) Disorders, Blood Transfusion Safety, Coagulation Therapy, Diabetes, Autoimmune Diseases, Cardiovascular Diseases, Neurology and Psychiatry.
    · Depending upon End User, the market is divided into Hospitals, Molecular Diagnostic Laboratories and Testing facilities, Academic Institutes, clinical care and Research Laboratories, Contract Research Organizations and Bio and health informatics companies.

    *Report Highlights:*

    · The report provides a detailed analysis on current and future market trends to identify the investment opportunities
    · Market forecasts till 2027, using estimated market values as the base numbers
    · Key market trends across the business segments, Regions and Countries
    · Key developments and strategies observed in the market
    · Market Dynamics such as Drivers, Restraints, Opportunities and other trends
    · In-depth company profiles of key players and upcoming prominent players
    · Growth prospects among the emerging nations through 2027
    · Market opportunities and recommendations for new investments

    *Key Topics Covered:*

    1 Market Outline
    1.1 Research Methodology
    1.2 Market Trends
    1.3 Regulatory Factors
    1.4 Product Analysis
    1.5 End User Analysis
    1.6 Strategic Benchmarking
    1.7 Opportunity Analysis

    2 Executive Summary

    3 Market Overview
    3.1 Current Trends
    3.1.1 Rising Prevalence Of Chronic Diseases
    3.1.2 Usage Of Combination Biomarkers For Diagnostics
    3.1.3 Adoption Of Complementary Medicine
    3.1.4 Growth Opportunities/Investment Opportunities
    3.2 Drivers
    3.3 Constraints
    3.4 Industry Attractiveness

    4 Personalized Medicine Market, By Therapeutic area
    4.1 Oncology
    4.2 Neurology
    4.3 Cardiology
    4.4 Antiviral
    4.5 Psychiatry

    5 Personalized Medicine Market, By Product
    5.1 Personalized Medicine Therapeutics
    5.1.1 Pharmaceuticals
    5.1.2 Genomic Medicine
    5.1.3 Medical Devices
    5.2 Personalized Medicine Diagnostics
    5.2.1 Genetic Testing
    5.2.2 Direct-to-consumer Diagnostics
    5.2.3 Esoteric Lab Services & Lab Tests
    5.3 Personalized Medical Care
    5.3.1 Telemedicine
    5.3.2 Healthcare Information Techno
    5.3.3 Diseases Management
    5.4 Personalized Nutrition & Wellness
    5.4.1 Retail Nutrition
    5.4.2 Complementary Medicine
    5.4.3 Alternative Medicine

    6 Personalized Medicine Market, By Capacity
    6.1 Companion Diagnostics
    6.2 Biomarker identification
    6.3 Health Informatics
    6.4 Clinical Research
    6.5 Cancer Management
    6.6 Infectious Diseases
    6.7 Central Nervous System (Cns) Disorders
    6.8 Blood Transfusion Safety
    6.9 Coagulation Therapy
    6.10 Diabetes
    6.11 Autoimmune Diseases
    6.12 Cardiovascular Diseases
    6.13 Neurology
    6.14 Psychiatry

    7 Personalized Medicine Market, By End User
    7.1 Hospitals
    7.2 Molecular Diagnostic Laboratories and Testing facilities
    7.3 Academic Institutes
    7.4 Clinical care and Research Laboratories
    7.5 Contract Research Organizations
    7.6 Bio and health informatics companies

    8 Personalized Medicine Market, By Geography

    9 Key Player Activities
    9.1 Acquisitions & Mergers
    9.2 Agreements, Partnerships, Collaborations and Joint Ventures
    9.3 Product Launch & Expansions
    9.4 Other Activities

    10 Leading Companies· Siemens Healthcare Diagnostics Inc.
    · Laboratory Corporation of America
    · Becton Dickinson & Co.
    · Foundation Medicine Inc.
    · Bristol-Myers Squibb
    · 3G Biotech
    · Quest Diagnostics
    · Abbott
    · Agendia NV
    · Asuragen Inc
    · Biogen, Inc.
    · F. Hoffmann-La Roche Ltd.
    · Thermo Fisher Scientific, Inc.
    · Bayer AG
    · Novartis AG

    For more information about this report visit https://www.researchandmarkets.com/research/7fs4jr/global?w=12
    Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

    CONTACT:
    CONTACT: ResearchAndMarkets.com
    Laura Wood, Senior Press Manager
    press@researchandmarkets.com
    For E.S.T Office Hours Call 1-917-300-0470
    For U.S./CAN Toll Free Call 1-800-526-8630
    For GMT Office Hours Call +353-1-416-8900
    Related Topics: Genomics Reported by GlobeNewswire 2 hours ago.

    0 0

    CHARLOTTESVILLE, Va., Nov. 29, 2018 (GLOBE NEWSWIRE) -- *Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW)*, www.adialpharma.com, a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder, today announced that it has established a Scientific Advisory Board (SAB) and has appointed Dr. Giovanni Addolorato, a leading global expert in the field of alcohol use disorder (AUD), as its first member and Chairperson. The SAB will help to guide the Company’s strategy and advance AD04, its lead therapeutic agent for AUD, with Phase 3 trials expected to commence in the first half of 2019.Dr. Addolorato is a professor of Gastroenterology and Hepatology at the Department of Gastroenterology and Endocrino-Metabolic Sciences at the Catholic University of Rome. He is also the Director of the “Alcohol Use Disorder and Alcohol Related Disease” Unit at the Catholic University of Rome, and is a senior consultant of Internal Medicine, Gastroenterology and Liver Diseases at the Catholic University of Rome. He has published more than 600 publications on pharmacology and neurobiology of alcohol use disorders including therapeutics and treatment, and alcohol liver disease. More than 220 of his publications have been included in peer reviewed journals and have been featured in Lancet, Molecular Psychiatry, Journal of Hepatology, American Journal of Medicine, American Journal of Clinical Nutrition, American Journal of Gastroenterology, Journal of Internal Medicine, Alcoholism: Clinical and Experimental Research. He is an associate Editor of “Alcologia: European Journal of Alcohol Studies” and a is member of several Editorial Boards including, “World Journal of Gastroenterology”, “Alcohol & Alcoholism”, “European Addiction Research”, “Journal of Addiction”, “Journal of Alcoholism and Drug Dependence” and “World Journal of Hepatology.” He has lectured at numerous international meetings and has received several prizes for his work. Since 2006, Dr. Addolorato has been a member of the European Research Advisory Board (ERAB). Since 2009, he has also been a member of the National Anti-Drugs Commission of the Department for Anti-Drug Policies, Office of the Government of Italy.

    Dr. Addolorato commented, “I am delighted to join Adial Pharmaceuticals’ SAB given the overwhelming market need for effective alcohol use disorder treatment and Adial’s encouraging Phase 2b data, which also showed a strong safety profile without the negative side effects of current drugs on the market.  I look forward to supporting the ongoing development AD04, which is designed to reduce cravings without the requirement of abstinence prior to or during treatment.”

    William Stilley, CEO of Adial Pharmaceuticals, stated, “We are pleased to officially launch our new Scientific Advisory Board to support the development efforts of AD04, our lead product candidate. We welcome Dr. Addolorato as the first member of our SAB, as he brings tremendous knowledge and experience in AUD and is expected to play an integral role as we prepare to begin our Phase 3 clinical trial.”

    *About Adial Pharmaceuticals, Inc.*

    Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company’s lead investigational new drug product, AD04, is a genetically targeted therapeutic agent for the treatment of alcohol use disorder (“AUD”). A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). The Company plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company’s proprietary companion diagnostic genetic test. AD04 is also believed to have the potential to treat other addictive disorders such as opioid use disorder, gambling, and obesity.

    *About Alcohol Use Disorder*

    According to an article in the widely respected publication The Lancet, alcohol is the number one cause of death globally among both men and women ages 15 to 49 years. In the United States alone, approximately 35 million people have AUD resulting in significant health, social and financial costs (NIAAA Alcohol Facts & Statistics). AUD contributes to over 200 different diseases, and 10% of children live with a person that has an alcohol problem. According to the American Society of Clinical Oncologists, 5-6% of new cancers and cancer deaths globally are directly attributable to alcohol. The Centers for Disease Control (CDC) has reported that AUD costs the U.S. economy about $250 billion annually, with heavy drinking accounting for greater than 75% of the social and health related costs. In addition, according to the NIAAA, the problem in the United States appears to be growing with an approximately 50% increase in AUD prevalence between 2002 and 2013.

    Despite the high prevalence and high costs, according to an article in the JAMA 2015 publication, only 7.7% of patients (i.e., approximately 2.7 million people) with AUD are estimated to have been treated in any way and only 3.6% by a physician (i.e., approximately 1.3 million people). The most common treatments for AUD are directed at achieving abstinence and typical treatments include psychological and social interventions. Most therapies require abstinence even prior to initiating therapy. Abstinence requires dramatic lifestyle changes often with serious work and social consequences. Significant side effects of current pharmacologic therapies include mental side effects such as psychiatric disorders and depressive symptoms and physical side effects such as nausea, dizziness, vomiting, abdominal pain, arthritis and joint fitness. These problems with the currently available therapies appear to limit the willingness of people with AUD to seek treatment and then to limit compliance with treatment requirements and, therefore, the ultimate results for many people attempting currently available therapies.

    *Forward Looking Statements*

    This communication contains certain “forward-looking statements” within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements are based upon current beliefs, expectations and assumptions and include statements regarding commencing Phase 3 clinical trials in the first half of 2019, the expected benefit AD04 will bring to patients and the expected role Dr. Addolorato will play in connection with the Phase 3 clinical trial. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, our ability commence the Phase 3 clinical trials in the first half of 2019, the ability of AD04 therapy to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results, the contribution of Dr. Addolorato to advancing our Phase 3 clinical trial of AD04, the ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to our  ability to promote or commercialize our product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate, our ability to establish and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund its research and development activities, and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our registration statement on Form S-1 that we have filed with the SEC and the final prospectus. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.

    *Contact:*

    Crescendo Communications, LLC
    David Waldman
    Tel: 212-671-1021
    Email: dwaldman@crescendo-ir.com Reported by GlobeNewswire 2 hours ago.

    0 0

    The global e-commerce logistics market was largely dominated by two leading players DHL International GmbH and FedEx Corporation who held 50% share in the global market in 2015.

    Albany, New York, Nov. 29, 2018 (GLOBE NEWSWIRE) -- According to TMR, the global e-commerce logistics market is anticipated to reach US$781 bn by the end of 2024 progressing from US$122.2 bn earned in 2014. During the forecast period between 2016 and 2024, the market is projected to rise at remarkable 20.6% CAGR.

    The global e-commerce logistics market was largely dominated by two leading players DHL International GmbH and FedEx Corporation who held 50% share in the global market in 2015. XPO Logistics and United Parcel Service Inc. are the other two companies functioning in the global market but contribution is far less than the first two mammoth companies are. Some of the other players operating the global e-commerce logistics market are Clipper Logistics Plc., Gati Limited, Kenco Group, Inc., and Aramex International. Several leading players in the market tapping the regional market in emerging economies such as in India and China. The promising growth potential offered in the e-commerce logistics market is likely to draw interest of new players that could help them grow extensively. Route optimization and innovative parcel tracking are strategies used by new players to attain a competitive edge in the market.

    *Get a PDF Sample - *https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=12806       

    Based on service type, the transportation segment held maximum share in the market in 2015 and was greater than the warehousing segment. The importance of transportation is more in the whole chain of e-commerce logistics process and it is gaining more and more importance as various large and small companies are focusing on last-mile delivery. On regional front, Asia Pacific is leading the global e-commerce logistics market as 60% of the global population resides in this regions who have created increased the overall demand through e-commerce medium.  North American and Europe also offered lucrative opportunity due to excellent digital infrastructure.

    *Ask for a PDF Brochure -* https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=12806     

    *Adopting Modern Way of Doing B2C E-Commerce Business to Fuel E-Commerce Logistics Market*

    Recent technological advancements have increased working efficiency in various sectors. One of them is e-commerce logistics. Massive growth in internet penetration, burgeoning cross-border e-commerce activities, and increasing focus on emerging economies are some of the major reasons behind the growth of e-commerce market at the global level. Moreover, adopting modern way of doing B2C e-commerce business is widely adopted by various companies. This B2C e-commerce business model forces the players to modifying their business model various times in year. Massive growth of innovative technologies is the key factor for the growth of the global e-commerce logistics market. Adding further, rising number of e-commerce startups in India, Brazil, and Mexico is likely are expected to provide fillip to the e-commerce logistics market.

    *Request a Custom Report -* https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=12806         

    *Infrastructural Issues in Emerging Economies to Deter Market Growth *

    *One of the major challenge faced by the players function in the e-commerce logistics market is infrastructural issues in emerging economies that hampers the service of last mile connectivity offered by them. In addition, when customer order online keeping the minimum limit in mind and then after receiving they return the unwanted product has high impacted the market players. It is mainly done to avail various offers initiated by companies.  But this put pressure on the chain of reverse logistics and triggers the expenses incurred by the companies in this market.*

    *View Report TOC - *https://www.transparencymarketresearch.com/report-toc/12806   

    The information presented in this review is based on a TMR report, titled “E-commerce Logistics Market (Service Type - Warehousing (Mega Centers, Hubs/Delivery Centers, Returns Processing, Centers), Transportation (Air/Express Delivery, Freight/Rail, Trucking/Over Road, Maritime)) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024.”

    *Global E-commerce Logistics Market has been segmented as presented below:*

    *Global E-commerce Logistics Market, by Service Type*

    · Warehousing

    · Mega Centers
    · Hubs/Delivery Centers
    · Returns Processing Centers

    · Transportation

    · Air/Express Delivery
    · Freight/Rail
    · Trucking/Over Road
    · Maritime

    · Others

    *Global E-commerce Logistics Market, by Operational Area*

    · Domestic
    · International

    *Global E-commerce Logistics Market: Geography*

    · *North America*

    · U.S.
    · Canada

    · *Europe*

    · U.K.
    · Italy
    · Spain
    · France
    · Germany
    · Rest Of Europe

    · *Asia Pacific Excluding Japan*

    · China
    · India
    · ASEAN
    · Rest Of Asia Pacific
    · Japan

    · *Latin America*

    · Brazil
    · Mexico
    · Rest of South America

    · *Middle East & Africa (MEA)*

    · GCC
    · South Africa
    · Rest of MEA

    *Browse More **IT & Telecom Market Research Reports*

    *Popular Research Reports by TMR:*

    · *E-Commerce Automotive Aftermarket: *https://www.transparencymarketresearch.com/e-commerce-automotive-aftermarket-market.html   
    · *M-Commerce Payments Market: *https://www.transparencymarketresearch.com/m-commerce-payments-market.html            
    · *Digital Freight Brokerage Market: *https://www.transparencymarketresearch.com/digital-freight-brokerage-market.html         

    *About Us: *
    *                                                                *
    Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

    Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

    TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

    *Contact Us*

    Mr. Rohit Bhisey
    Transparency Market Research
    State Tower,
    90 State Street,
    Suite 700,
    Albany NY - 12207
    United States
    Tel: +1-518-618-1030
    USA - Canada Toll Free: 866-552-3453
    *Email*: sales@transparencymarketresearch.com
    *Website*: http://www.transparencymarketresearch.com
    *Research Blog:* http://www.techyounme.com/ Reported by GlobeNewswire 1 hour ago.

    0 0

    Dublin, Nov. 29, 2018 (GLOBE NEWSWIRE) -- The "From Cigarettes to Vaping - The Factors for Change" report has been added to *ResearchAndMarkets.com's* offering.This market report compares data on six countries - the UK, France, Italy, the US, Russia, and Germany - to identify factors that impact consumer choice when switching to vaping, including the range of products available, distribution coverage, and affordability.

    We also found that the UK is the best served country by vape stores in terms of area coverage, while the country with the best access is France. Vaping is most affordable in Germany and the US.

    *Key Topics Covered:*1 Executive summary

    2 Introduction

    3 Online hardware

    4 Distribution coverage

    5 Affordability

    6 Cigarettes

    *Companies Mentioned *· Eleaf
    · Innokin
    · Joyetech
    · Kanger
    · Smok
    · Vaporesso
    · Wismec

    For more information about this report visit https://www.researchandmarkets.com/research/8bzqrf/factors_impacting?w=12
    Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

    CONTACT:
    CONTACT: ResearchAndMarkets.com
    Laura Wood, Senior Press Manager
    press@researchandmarkets.com
    For E.S.T Office Hours Call 1-917-300-0470
    For U.S./CAN Toll Free Call 1-800-526-8630
    For GMT Office Hours Call +353-1-416-8900
    Related Topics: Tobacco, E-Cigarettes Reported by GlobeNewswire 1 hour ago.

    0 0

    Study reveals new model for measuring employer reputation and the pivotal importance of workplace culture and values in shaping corporate reputation

    Boston, MA, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Reputation Institute (RI), the world’s leading provider of reputation measurement, management and intelligence services, today announced the company’s first ever Employer of Choice RepTrak® study naming the world’s 10 most reputable employers with the greatest “Willingness to Work For” scores from the General Public.

    The top 10 employer leaders globally recognized in RI’s 2018 Employer of Choice RepTrak® are (in alphabetical order):

    · 3M [NYSE: MMM]
    · BMW Group [OTCMKTS: BMWYY]
    · Bosch [NSE: BOSCHLTD]
    · Canon [NYSE: CAJ]
    · Google [NASDAQ: GOOGL]
    · Intel [NASDAQ: INTC]
    · The LEGO Group
    · Microsoft [NASDAQ: MSFT]
    · Netflix [NASDAQ: NFLX]
    · The Walt Disney Company [NYSE: DIS]

     
    The world’s largest reputation study of its kind, the Employer of Choice RepTrak is based on more than 230,000 individual ratings collected in the first quarter of 2018. It includes unique insights into the dynamics behind reputational impact. The global study shows what drives employer reputation, and the direct correlation between corporate reputation and stakeholder support.

    “The employee recruiting environment is increasingly challenging and highly competitive, with low unemployment and high employee turnover,” said Michele Tesoro-Tess, Executive Vice President and Market Leader at Reputation Institute. “The rubric for what it takes to be a great employer is quickly shifting. To be relevant as an Employer of Choice today, you need to be a progressive company with a moral conscience.”

    “While organizations have traditionally focused on workplace metrics to attract and retain employees, our analysis shows the most important drivers of intent to work for a company go beyond that,” said Sven Klingemann, Global Research Manager at Reputation Institute. “Key drivers of becoming an employer of choice include being innovative; delivering on high quality product experience at a good value; being ethical, environmentally conscious, and positively mindful of societal influence; as well as appealing leadership.”

    Key findings from the study demonstrate that Employer of Choice organizations enjoy competitive advantages — not only from an employer attractiveness perspective, but also encompassing a wide range of other supportive behaviors.  These supportive behaviors are reflected across diverse demographic groups, including Millennials, a key stakeholder group for employers.

    Study results indicate that to become an Employer of Choice companies need to be progressive in a sustainable way, create compelling corporate narrative to express what they stand for and embrace their cultural values, while also leveraging their CEO to humanize the company. To remain an Employer of Choice, companies need to continue to act ethically.

    For more information, view the 2018 Employer of Choice RepTrak webinar and download the report and full rankings at: https://www.reputationinstitute.com/global-employer-of-choice-reptrak

    *Learn More and Know Your Reputation Score *
    Annually, RI measures the reputation of thousands of companies using the RepTrak framework, including measures of the most highly regarded multinational companies in 15 countries including Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Russia, South Korea, Spain, the United Kingdom and the United States.

    To get your company’s 2018 score and learn how you can improve your ranking and grow your stakeholder support, just ask us at: https://www.reputationinstitute.com/about/Contact-Us*.

    About Reputation Institute
    *Reputation Institute (RI) powers the world’s most reputable companies. We are a data-driven, reputation insights advisory firm, and provider of peer-to-peer membership services. By mining media conversations, measuring stakeholder perceptions and providing reputation management services, we unleash the potential of Reputation Intelligence to build better companies. Our proprietary RepTrak® model tracks and analyzes the reputation of companies, CEOs, cities, and countries. We are most widely known for the Forbes-published Global RT100.  Learn more at: http://www.reputationinstitute.com.

    CONTACT: Karen Hopp
    Bazini Hopp for Reputation Institute
    917-514-1723
    karen@bazinihopp.com Reported by GlobeNewswire 1 hour ago.

    0 0

    Anushka Sharma and Virat Kohli tied the knot in an intimate ceremony in Italy on December 11 last year. …read more Source:: NEWS 18       

    The post This is Where Virat Kohli, Anushka Sharma Will Celebrate Their First Wedding Anniversary appeared first on Bollywood latest news. Reported by Filmy Friday 23 minutes ago.

    0 0

    England retain top-five standing as Germany slip to 16th in world rankings Belgium continue to lead the way, just ahead of France, while there is mixed fortunes for fallen giants such as Die Mannschaft, Argentina and Italy Reported by Goal.com 24 minutes ago.

older | 1 | .... | 1065 | 1066 | (Page 1067) | 1068 | 1069 | .... | 1077 | newer